journal article·2017-02

Targeted hydroxyethyl starch prodrug for inhibiting the growth and metastasis of prostate cancer

Kaidong Zhao, Di Li, Weiguo Xu, Jianxun Ding, Weiqian Jiang, Mingqiang Li, Chunxi Wang, Xuesi Chen

Biomaterials· Volume 116
Publisher page

Abstract

Prostate cancer is one of the most prevalent malignancies among men. Although chemotherapy has been an effective therapeutic approach for treating metastatic prostate cancer, serious undesired side effects have hampered its wide application clinically. In this work, a pH-responsive LHRH-conjugated hydroxyethyl starch-doxorubicin (HES-DOX/LHRH) prodrug was facilely synthesized by conjugating oxidized HES (HES-CHO) with DOX and LHRH through an acid-sensitive Schiff base bond. The resulting prodrug spontaneously self-assembled into nanoscopic micelle with a radius of about 55 nm in an aqueous environment. HES-DOX/LHRH significantly improved the in vivo tissue distribution of the drug. Compared to its non-targeted counterpart, targeted HES-DOX/LHRH demonstrated a greater in vitro anti-proliferative capability toward mouse RM-1 prostate cells. More importantly, targeted HES-DOX/LHRH exhibited higher levels of anti-tumor and anti-metastasis activities against an RM-1-xenografted mouse model, with lower systemic toxicity compared to free DOX·HCl and non-targeted HES-DOX. Hence, these results revealed that targeted HES-DOX/LHRH possesses great potential application in clinical chemotherapy of metastatic prostate cancer.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Lanthanide and Transition Metal Complexes

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (56)

Show source-provided references
1. Cancer statistics, 2016
2. Nanodiamonds enhance therapeutic efficacy of doxorubicin in treating metastatic hormone-refractory prostate cancer10.1088/0957-4484/25/42/425103 ↗
3. Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer10.1073/pnas.1323102111 ↗
4. Androgens regulate prostate cancer cell growth via an AMPK-PGC-1alpha-mediated metabolic switch10.1038/onc.2013.463 ↗
5. Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels10.18632/oncotarget.2146 ↗
6. Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer10.1517/13543784.2011.574611 ↗
7. German working group on castration-resistant prostate, castration-resistant prostate cancer: Where we stand in 2013 and what urologists should know10.1016/j.eururo.2013.05.021 ↗
8. Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists10.1158/1078-0432.CCR-10-1113 ↗
9. Reduction-responsive polypeptide nanogel delivers antitumor drug for improved efficacy and safety10.1016/j.actbio.2015.08.049 ↗
10. Enhanced endocytosis of acid-sensitive doxorubicin derivatives with intelligent nanogel for improved security and efficacy10.1039/C3BM60024F ↗
11. The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer10.1016/j.ctrv.2008.05.004 ↗
12. Versatile preparation of intracellular-acidity-sensitive oxime-linked polysaccharide-doxorubicin conjugate for malignancy therapeutic10.1016/j.biomaterials.2015.03.021 ↗
13. Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies10.1016/j.yjmcc.2012.03.006 ↗
14. Polymer–drug conjugates: Origins, progress to date and future directions10.1016/j.addr.2012.10.014 ↗
15. Polymeric conjugates for drug delivery10.1021/cm2031569 ↗
16. Recent trends in the design of anticancer polymer prodrug nanocarriers10.1039/C3PY01384G ↗
17. Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery10.1021/ja207150n ↗
18. Preclinical evaluation of antitumor activity of acid-sensitive PEGylated doxorubicin10.1021/am506178c ↗
19. Understanding the Warburg effect: The metabolic requirements of cell proliferation10.1126/science.1160809 ↗
20. Tunable, ultrasensitive pH-responsive nanoparticles targeting specific endocytic organelles in living cells10.1002/anie.201100884 ↗
21. Role of integrated cancer nanomedicine in overcoming drug resistance10.1016/j.addr.2013.07.012 ↗
22. GnRH Receptors in cancer: From cell biology to novel targeted therapeutic strategies10.1210/er.2012-1014 ↗
23. Disulfide cross-linked polyurethane micelles as a reduction-triggered drug delivery system for cancer therapy10.1002/adhm.201300308 ↗
24. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide10.1073/pnas.0504274102 ↗
25. Suppressing unspecific cell uptake for targeted delivery using hydroxyethyl starch nanocapsules10.1021/bm300653v ↗
26. Drug binding rate regulates the properties of polysaccharide prodrugs10.1039/C6TB00991C ↗
27. Controlled shielding and deshielding of gene delivery polyplexes using hydroxyethyl starch (HES) and alpha-amylase10.1016/j.jconrel.2012.01.006 ↗
28. Dextran-based doxorubicin nanocarriers with improved tumor penetration10.1021/bm401526d ↗
29. Cisplatin crosslinked pH-sensitive nanoparticles for efficient delivery of doxorubicin10.1016/j.biomaterials.2014.01.018 ↗
30. Integrated self-assembling drug delivery system possessing dual responsive and active targeting for orthotopic ovarian cancer theranostics10.1016/j.biomaterials.2016.03.005 ↗
31. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs
32. Efficacious hepatoma-targeted nanomedicine self-assembled from galactopeptide and doxorubicin driven by two-stage physical interactions10.1016/j.jconrel.2012.12.006 ↗
33. Multi-functional self-fluorescent unimolecular micelles for tumor-targeted drug delivery and bioimaging10.1016/j.biomaterials.2015.01.006 ↗
34. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer10.1016/j.biomaterials.2016.05.041 ↗
35. Redox-sensitive shell-crosslinked polypeptide-block-polysaccharide micelles for efficient intracellular anticancer drug delivery10.1002/mabi.201300175 ↗
36. Injectable hydrogels based on poly(ethylene glycol) and derivatives as functional biomaterials10.1039/C4RA13581D ↗
37. Biocompatible reduction-responsive polypeptide micelles as nanocarriers for enhanced chemotherapy efficacy in vitro10.1039/C2TB00063F ↗
38. Targeted delivery of cisplatin by LHRH-peptide conjugated dextran nanoparticles suppresses breast cancer growth and metastasis10.1016/j.actbio.2015.02.022 ↗
39. Glutathione-degradable drug-loaded nanogel effectively and securely suppresses hepatoma in mouse model
40. Epirubicin-complexed polypeptide micelle effectively and safely treats hepatocellular carcinoma10.3390/polym7111521 ↗
41. Body distribution profile of polysaccharides after intravenous administration10.3109/10717549309031345 ↗
42. Derivation of MPR and TRAMP models of prostate cancer and prostate cancer metastasis for evaluation of therapeutic strategies10.1016/S1078-1439(01)00180-6 ↗
43. Tumor redox heterogeneity-responsive prodrug nanocapsules for cancer chemotherapy10.1002/adma.201300929 ↗
44. Synergistic antitumor effects of doxorubicin-loaded carboxymethyl cellulose nanoparticle in combination with endostar for effective treatment of non-small-cell lung cancer10.1002/adhm.201400108 ↗
45. Assessment of apoptosis by immunohistochemistry to active caspase-3, active caspase-7, or cleaved PARP in monolayer cells and spheroid and subcutaneous xenografts of human carcinoma10.1369/jhc.2008.952044 ↗
46. Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy10.1016/j.biomaterials.2013.01.063 ↗
47. Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice10.1016/j.jconrel.2009.07.005 ↗
48. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death10.1158/0008-5472.CAN-05-3410 ↗
49. Sentinel lymph node imaging by a fluorescently labeled DNA tetrahedron10.1016/j.biomaterials.2013.03.074 ↗
50. Treating metastatic cancer with nanotechnology10.1038/nrc3180 ↗
51. Clinical characteristics and prognostic factors of prostate cancer with liver metastases10.1007/s13277-013-1083-6 ↗
52. The role of inflammation in lung cancer10.1007/978-3-0348-0837-8_1 ↗
53. COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models10.1126/scitranslmed.3008455 ↗
54. Doxorubicin-loaded polysaccharide nanoparticles suppress the growth of murine colorectal carcinoma and inhibit the metastasis of murine mammary carcinoma in rodent models10.1016/j.biomaterials.2015.02.002 ↗
55. Terminology in cancer cachexia: Importance and status
56. Cancer-related inflammation and treatment effectiveness10.1016/S1470-2045(14)70263-3 ↗